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Edited by Robert BaroukiAbstract Fas/FasL interactions have been proposed as a poten-
tially important mechanism mediating b-cell death in type 1 dia-
betes. Recent investigations suggest RNA interference, aﬀorded
by small interfering RNAs (siRNA), can provide speciﬁc and ro-
bust gene silencing in mammalian cells. The current study at-
tempted to investigate the eﬀects of silencing Fas expression
with siRNA on Fas-mediated apoptosis in mouse insulinoma cells
following cytokine incubation. Our results indicate that siRNA is
capable of rapid inhibition of cytokine-induced Fas mRNA pro-
duction and cell surface Fas protein. A complete suppression of
the total Fas protein was only observed after prolonged incuba-
tion with siRNA, suggesting a slow turn-over of Fas protein.
Moreover, siRNA signiﬁcantly inhibited Fas-mediated b-cell
apoptosis assessed by Caspase-3 and terminal deoxynucleotidyl
transferase biotin-dUTP nick end labeling assays, the extent of
which positively correlated with the level of cell surface Fas.
These observations provide additional evidence supporting a role
for the Fas-mediated pathway in b-cell destruction, and suggest
that siRNA targeting Fas may be of therapeutic value in prevent-
ing type 1 diabetes and improving islet cell viability in transplan-
tation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Pancreatic b cells are destroyed by autoimmune responses in
type 1 diabetes, leading to insulin deprivation and hyperglyce-
mia [1]. Both CD4+ and CD8+ T cells are thought to be impor-
tant eﬀectors in b cell death. Multiple mechanisms contribute
to this destructive process [2], among which CD4+ T cells ap-
pear to damage b cells through at least two independent path-
ways mediated by Fas and nitric oxide (NO) [3].
Proinﬂammatory cytokines secreted by inﬁltrating lympho-Abbreviations: siRNA, small interfering RNA; NOD, non-obese
diabetic; RT-PCR, reverse transcription-polymerase chain reaction;
TUNEL, terminal deoxynucleotidyl transferase biotin-dUTP nick end
labeling; NO, nitric oxide
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doi:10.1016/j.febslet.2005.12.068cytes can upregulate Fas expression on b cells, thus activating
Fas signaling [4,5]. Cytokines can also stimulate inducible
nitric oxide synthase (iNOS) and subsequent NO formation,
leading to impairment in insulin secretion and DNA fragmen-
tation [3].
Fas/FasL interaction has been suggested to play an impor-
tant role in the natural development and recurrence of autoim-
mune diabetes in murine models [4–10]. The involvement of
Fas/FasL system may also hold true in the development of hu-
man type 1 diabetes, as suggested by histological investigation
of pancreas specimens from new onset patients [11]. However,
our understanding of Fas functions in autoimmune diabetes is
yet to be complete [12]. Despite a potentially important role of
Fas in b cell death, inhibition of this pathway has not been
fully explored as a diabetes treatment [10,13]. Anti-FasL anti-
body has been tested in non-obese diabetic (NOD) mice, but
only modest success was observed [10].
A growing body of the literature has provided convincing
evidence that RNA interference (RNAi), via small interfering
RNA (siRNA), can silence gene expression in a speciﬁc and
potent manner in mammalian cells [14,15]. Rapid progress
in siRNA delivery and function in vivo has further stimulated
interests in exploring this approach as a therapeutic platform
for human pathology [16–19]. As such, we believe siRNA
may represent a viable means for eﬃcient silencing of pro-
apoptotic genes including Fas and iNOS and may thereby
protect b cells from cytokine-induced apoptosis. In the cur-
rent study, we chose Fas as the ﬁrst target to assess the
potentiality of using siRNA to inhibit b cell death. To
achieve this goal, we developed a Fas-targeting siRNA and
evaluated its capability in silencing Fas expression and inhib-
iting Fas-mediated b cell damage in response to proinﬂamma-
tory cytokines. We ﬁrst tested this possibility in transformed
b cell lines.2. Materials and methods
2.1. Fas siRNA
The 21-nt siRNA duplex was provided in the 2 0-deprotected and de-
salted form of 2 0-O-ACE-RNA (Dharmacon). Cy3-labeled siGLO
RISC-free siRNA (Dharmacon) was used to visualize transfection eﬃ-
ciency. Three siRNA sequences were designed based on the murine Fas
mRNA sequence (GenBank Accession No. NM_007987) following the
Rational siRNA Design algorithm [20]. Fas1 siRNA, beginning at nt
415, 5 0-GUG CAA GUG CAA ACC AGA C dTdT-3 0 (sense), and
5 0-GUC UGG UUU GCA CUU GCA C dTdT-3 0 (antisense). Fas2blished by Elsevier B.V. All rights reserved.
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dTdT-3 0 (sense), and 5 0-GUU CUG CGA CAU UCG GCU U dTdT-
3 0 (antisense). Fas3 siRNA (control siRNA), beginning at nt 613, 5 0-
GUA CCG GAA AAG AAA GUG C dTdT-3 0 (sense), 5 0-GCA
CUU UCU UUU CCG GUA C dTdT-3 0 (antisense).
2.2. Cell culture, transfection and cytokine treatment
Murine insulinoma NIT-1 cells and bTC-3 cells were used in the
study. NIT-1 cells were cultured in RPMI 1640 supplemented with
10% fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, 100 U/
ml penicillin, and 0.1 mg/ml streptomycin (37 C, 5% CO2). bTC-3 cells
were cultured in DMEM supplemented with 13.5% horse serum, 2.2%
fetal bovine serum, 25 mMHEPES, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin (37 C, 5% CO2). At 30–60% conﬂuency, cells were trans-
fected with 40 nM Fas siRNA complexed with Lipofectamine 2000
(Invitrogen) for 3 days (3-day experiment) or 9 days (ﬁrst transfection
on day 0 and second on day 4, 9-day experiment) prior to cytokine
treatment with 100 U/ml mIL-1b and 1000 U/ml mIFN-c (Sigma) for
16 h. During the 9-day experiment, cells were split 1:2 to avoid over-
conﬂuence, if necessary. For induction of apoptosis, cells were incu-
bated with anti-mouse Fas Jo2 antibody (5 lg/ml, Pharmingen) and
protein G (2 lg/ml) for 24 h following cytokine exposure. Floating
cells were collected and counted. Adherent cells were harvested by
trypsin-EDTA for RNA extraction, ﬂow cytometry, and immunocyto-
chemistry.
2.3. Semiquantitative and real-time RT-PCR analysis
Total RNA was extracted using Trizol (Invitrogen) and treated with
RNase-free DNase I (Invitrogen). Semiquantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR) was performed with Access-
Quick RT-PCR system (Promega) for 30 cycles. The primers for Fas
mRNA were 500-TGGCTCACAGTTAAGAGTTCATACTCAAGG-
TAC-3 0 (forward) and 5 0-ATTGGTA TGGTTTCACGACTGGAGG-
TTCTA-3 0 (reverse). The primers for GAPDH mRNA were 5 0-TGC-
TGAGTATGTCGTGGAGTCTA-3 0 (forward), and 5 0-AGTGGGA-
GTT GCTGTTGAAGTCG-30 (reverse). Real-time RT-PCR was per-
formed with TaqMan One-Step RT-PCRMaster Mix Reagent kit (Ap-
plied Biosystems Cat# 4309169) and detected with ABI Prism 5700
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). A 25 ll reaction mixture contained 100 ng of total RNA,
12.5 ll 2 · Taqman PCR Mix, 0.625 ll 40 · reverse transcriptase,
300 nM forward and reverse primers (5 0-GCGATTCTCCTGGCTGT-
GAA-3 0 forward, 5 0-TGGCTCAAGGGTTCCATGTT-3 0 reverse),
and 150 nM TaqMan probe (5 0-CTGTGTTCGCTGCGCCTCGTG-
3 0). Reactions were incubated at 48 C for 2 min, 95 C for 10 min,
and then ampliﬁed for 40 cycles (95 C for 15 s followed by 60 C for
1 min in each cycle).RibosomalRNA levels provide an endogenous con-
trol for PCRquantiﬁcation studies. The TaqManRibosomal RNA con-
trol Reagents (Applied Biosystems Cat# 4308329) were used for the
target quantiﬁcation normalized to an endogenous control 18s rRNA.
As the ampliﬁcation eﬃciency of FasmRNA in bTC-3 cells was approx-
imately equal to that of 18s rRNA, the relative quantiﬁcation of Fas
mRNA in bTC-3 cells was expressed using the 2DDCt (fold diﬀerence)
method [21] uponnormalization to 18s rRNAand relative to a calibrator
(untreated control).Ct is the cycle number atwhich the amount of ampli-
ﬁed gene of interest reaches a ﬁxed threshold, DCt = Ct of target gene
(Fas)  Ct of endogenous control (18s), and DDCt = DCt of sam-
ples  DCt of calibrator. As the ampliﬁcation eﬃciency of Fas mRNA
inNIT-1 cells was diﬀerent from that of 18s rRNA, standard curveswere
included in each run. The amount of FasmRNAand 18s rRNAwas cal-
culated from the standard curves, and the relative quantiﬁcation of Fas
mRNA in NIT-1 cells was expressed as (the amount of Fas mRNA
divided by the amount of 18s rRNA).
2.4. Flow cytometric analysis
For detection of cell surface Fas, 1 · 106 live cells were incubated
with 1:100 Alexa 488-conjugated hamster anti-mouse Fas antibody
(Jo2, Pharmingen) or 1:100 Alexa 488-conjugated hamster IgG2
(Pharmingen) as negative control for 30 min at 4 C. For detection
of total Fas, cells were ﬁxed with 1% paraformaldehyde and permeabi-
lized with 0.1% Triton X-100 prior to incubation with 1:100 rabbit
anti-mouse Fas antibody (X-20, Santa Cruz) or rabbit IgG as negative
control, followed by incubation with 1:3000 Qdot 705-conjugated
Goat anti-rabbit IgG (Quantum Dot). For detection of active Cas-pase-3, cells were ﬁxed, permeabilized and incubated with 1:100 PE-
conjugated rabbit anti-Caspase-3 recognizing the active form of the en-
zyme (Pharmingen), or rabbit Ig detected by biotinylated anti-rabbit Ig
and streptavidin-PE as negative control. Cells were analyzed with LSR
II (BD Pharmingen, San Diego, CA, USA) acquiring 100,000
events per sample. Unstained cells and isotype controls were run
concurrently.
2.5. Immunocytochemistry and TUNEL assay
Cells were cytospun on Superfrost Plus slides (Fisher), air dried for
30 min and stored at 80 C until staining. For Fas detection, cells
were ﬁxed with 20 C acetone, blocked with 5% goat serum, incu-
bated with 1:20 rabbit anti-mouse Fas antibody (M-20, Santa Cruz),
followed by biotinylated goat anti-rabbit IgG, and detected with
ABC Alkaline Phosphatase Kit and Vector Blue chromogen (Vectors).
Cells were counterstained by Nuclear Fast Red. The terminal deoxynu-
cleotidyl transferase biotin-dUTP nick end labeling (TUNEL) assay
was performed with Apoptosis Detection Kit (Upstate). Apoptotic
cells with FITC-dUTP-labeled DNA (green ﬂuorescence) were visual-
ized by ﬂuorescent microscopy (Olympus IX-71, Melville, New York,
USA) and images were taken at the same exposure time. Cell nuclei
were stained with DAPI (blue ﬂuorescence). Percentage of Fas+ cells
and apoptotic cells were counted with Microsuite Imaging Software
(SIS, Lakewood, Colorado, USA), in a blinded fashion, from six
10 · ﬁelds per slide and two slides per condition.
2.6. Statistical analysis
All experiments were repeated two or three times with duplicate
samples each time. Results were presented as means ± S.E.M. Statisti-
cal analysis was performed using one-way ANOVA test and statistical
signiﬁcance is deﬁned as P < 0.05.3. Results and discussion
In the current study, we attempted to evaluate the ability of
siRNA targeting Fas in inhibiting Fas-mediated pancreatic b-
cell apoptosis in face of proinﬂammatory cytokines. Two
mouse insulinoma cell lines, NIT-1 (derived from NOD mice)
and bTC-3 (derived from C57BL/6 mice) cells, were investi-
gated. The purpose of this choice was to test whether Fas
siRNA would work in two distinct b cell lines varied in mouse
origin and morphological characteristics.
In order to achieve suﬃcient siRNA transfection, four trans-
fection reagents were tested, including Lipofectamine 2000
(Invitrogen), Transmessenger (Qiagen), siPORT Amine and si-
PORT Lipid (Ambion). Only Lipofectamine 2000 facilitated
successful delivery (>90%) of Cy3-labeled siRNA into both
NIT-1 and bTC-3 cells with 85–95% viability (Fig. 1). No
Cy3 ﬂuorescence was detected in control cells that were un-
treated, or treated in the absence of Lipofectamine 2000 or
siRNA. A rapid uptake of siRNA was observed within
30 min post transfection (data not shown), and the presence
of Cy3 ﬂuorescence persisted for at least four days, albeit at
a reduced level and in a lower percentage of cells, suggesting
slow degradation and dilution of synthetic siRNA molecules.
In order to investigate the eﬀects of siRNA on Fas-mediated,
cytokine-induced apoptosis, cytokine concentrations required
titration to minimize the impact of NO pathway. It has been
shown that Fas and NO productions in b cells are dose-depen-
dent on cytokines [22–24]. Cell surface Fas levels appeared to
continuously increase within a wide range of IL-1b and IFN-c
concentrations [22], while cytokine-stimulated nitrite release
reached a plateau at 10–25 U/ml of IL-1b [23,24]. Our preli-
minary experiments that examined various IL-1b and IFN-c
concentrations on cell surface Fas and nitrite production in
Fig. 1. Delivery of siRNAs. NIT-1 cells (A–D) and bTC-3 cells (E–H) were transfected at 30% conﬂuency with 20 nM Cy3-siRNA delivered by
Lipofectamine 2000 (A, B, E–H), or with 20 nM Cy3-siRNA alone (C, D). 24 h (A–F) or 96 h (G, H) post-transfection, cells were examined for
morphology using light microscope (A, C, E, G) and for siRNA uptake using ﬂuorescent microscope (B, D, F, H).
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not shown). IL-1b and IFN-c (100 + 1000 U/ml) appeared to
maximally diﬀerentiate the eﬀects of Fas from the NO path-
way, and therefore, this concentration was used in the current
study.
To identify a functional Fas siRNA, three siRNA candidates
were designed based on the murine Fas mRNA sequence (Gen-
Bank Accession No. NM_007987). NIT-1 cells were treated
with 40 nM siRNA molecules for 3 days prior to overnightFig. 2. Identiﬁcation of eﬃcient Fas siRNA. (A) Semiquantitative RT-PCR
using total RNA isolated from untreated cells, cytokine-treated cells, and ce
followed by cytokine incubation. (B) Real-time RT-PCR of Fas mRNA follo
by 18s rRNA, and the values of untreated cells were set at 1. \P < 0.01,
incubation with siRNA. ND, non-detectable.incubation with proinﬂammatory cytokines IL-1b and IFN-c
(100 + 1000 U/ml). The silencing eﬀects on Fas transcription
were evaluated by semi-quantitative and real-time RT-PCR
analyses (Fig. 2A and B). Cytokine exposure markedly stimu-
lated Fas mRNA levels by 7-fold in the control cells. This
induction was signiﬁcantly inhibited by 74% and 90% by
Fas1 and Fas2 siRNAs, respectively, while Fas3 siRNAs did
not have any appreciable eﬀects. The observed suppression
was speciﬁc to Fas mRNA and did not aﬀect GAPDHampliﬁcation of the Fas and GAPDH mRNA levels was performed
lls treated with Fas1, Fas2, and Fas3 siRNAs for 3 days individually
wing 3-day incubation with siRNA. Fas mRNA levels were normalized
\\P < 0.001. (C) Real-time RT-PCR of Fas mRNA following 9-day
556 B.R. Burkhardt et al. / FEBS Letters 580 (2006) 553–560transcription. Therefore, in further experiments we utilized
Fas2 siRNA (referred to as Fas siRNA) to silence Fas expres-
sion and used Fas3 siRNA as control (referred to as control
siRNA).
We then evaluated with ﬂow cytometry whether Fas siRNA
could reduce Fas protein levels (Fig. 3). In the control cells, the
levels of total Fas protein slightly increased with cytokine
exposure (Fig. 3A), however, a much greater elevation oc-
curred with cell surface Fas (>15-fold, P < 0.001, Fig. 3B).
This observation was consistent with previous reports from
Augstein et al. that cytokines stimulated rapid translocation
of intracellular Fas to cell membrane [22,25]. Interestingly, de-
spite the marked suppression of Fas mRNA levels, Fas siRNA
did not result in a signiﬁcant reduction in the total Fas protein
concentrations. However, the cytokine-induced cell surface
Fas was signiﬁcantly decreased by 42–51% (P < 0.05). These
results suggest that the short-term inhibition of Fas mRNA
expression did not aﬀect the pool of total Fas protein, but
downregulated Fas traﬃcking to cell surface.
Mammalian proteins have a diverse range of half-life (i.e.,
from minutes to days). One possible explanation for the ob-
served discordance between Fas mRNA and total protein lev-
els in the 3-day study was that Fas may have a slow turnover
rate. To test this possibility, we treated cells with Fas siRNA
for 9 days in repeated transfections to see whether prolonged
inhibition would result in a complete knock-down of Fas
expression in both mRNA and protein levels (Fig. 3C and
D). As expected, Fas siRNA not only suppressed Fas mRNA
transcripts (Fig. 2C) as observed in the 3-day study, but com-Medium Control siRNA Fas siRNA
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Our observations therefore support the notion that that cell
surface Fas might come from two distinct pools of Fas protein,
one located in intracellular compartments with a slow turn-
over, the other being newly synthesized Fas that appears to
preferentially transport to cell surface [22,25].
Our next objective was to determine whether silencing of Fas
expression could protect b cells from apoptosis. To induce Fas-
mediated apoptosis, cells were incubated with anti-mouse Fas
Jo2 antibody and protein G following cytokine exposure. Cas-
pase-3 is a central eﬀector in various apoptotic pathways lead-
ing to DNA fragmentation and cell death. Increased Caspase-3
activity has been consistently observed in b cell apoptosis in-
duced by diverse apoptotic stimuli including cytokines, high
glucose, NO, and free fatty acids [26–30]. Speciﬁcally, cyto-
kines or glucose caused b cell death by stimulating caspase cas-
cade via upregulation of Fas [26,27]. Therefore, we evaluated
the levels of active Caspase-3 in NIT-1 cells by ﬂow cytometry
using an antibody speciﬁc for the active form of this enzyme
(Fig. 4). Our data indicated that the basal level of Caspase-3
activity was low in resting NIT-1 cells (0.5–3%), which was
markedly stimulated to 18–25% by overnight cytokine expo-
sure (P < 0.001). Incubation with Fas siRNA for 3 days re-
duced cytokine-stimulated Caspase-3 by approximately 50%,
and this suppression was nearly complete following the 9-day
incubation (Figs. 4 and 5A and B). Further analysis revealed
a positive correlation between Caspase-3 and cell surface Fas
(r = 0.875, P < 0.05), while changes in total Fas levels didMedium Control siRNA Fas siRNA
Ce
ll 
Su
rfa
ce
 F
as
 (%
)
0
5
10
15
20
- cytokine 
+ cytokine 
*
Medium Control siRNA Fas siRNA
Ce
ll 
su
rfa
ce
 F
as
 (%
)
0
5
10
15
20
25
-cytokine 
+cytokine 
**
lls. Cells were treated with medium, control siRNA or Fas siRNA for 3
d IFN-c (gray bar) or without cytokines (black bar). The percentage of
ere analyzed with ﬂow cytometry. \P < 0.05, \\P < 0.01, Fas siRNA vs.
NA vs. medium or control siRNA, without cytokine exposure.
100 101 102 103 104
Cas-3 PE
0
20
0
40
0
60
0
N
um
be
r
100 101 102 103 104
Cas-3 PE
0
10
0
20
0
30
0
40
0
N
um
be
r
100 101 102 103 104
Cas-3 PE
0
10
0
20
0
30
0
40
0
N
um
be
r
100 101 102 103 104
Cas-3 PE
0
10
0
20
0
30
0
40
0
N
um
be
r
100 101 102 103 104
Cas-3 PE
0
10
0
20
0
30
0
40
0
N
um
be
r
100 101 102 103 104
Cas-3 PE
0
10
0
20
0
30
0
40
0
N
um
be
r
9 Day 
3 Day 
Medium Control siRNA Fas siRNA
- Cytokine + Jo2 + Cytokines + Jo2
0.55%
22.7%
0.97%
24.7%
1.20%
15.7%
3.04%
18.2%
2.61%
18.2%
0.21%
0.38%
Fig. 4. Representative ﬂow cytometric histograms of Fas-mediated active Caspase-3 in NIT-1 cells. Cells were treated with medium, control siRNA,
or Fas siRNA for 3 or 9 days (incubation 1), 16-h medium or cytokine (incubation 2), followed by 24-h incubation with Jo2 antibody and protein G
(incubation 3). Percentage of cells carrying active caspase-3 is presented for each condition.
Medium Control siRNA Fas siRNA
A
ct
iv
e 
Ca
sp
as
e-
3 
(%
) 
0
5
10
15
20
25
30
- cytokine 
+ cytokine 
*
+ Jo2
+ Jo2 
3-day Study
Cell Surface Fas (%)
0 5 10 15 20 25 30
A
ct
iv
e 
Ca
sp
as
e-
3 
(%
)
0
5
10
15
20
25
30
r=0.875
Total Fas (%)
0 20 40 60 80
A
ct
iv
e 
Ca
sp
as
e-
3 
(%
)
0
5
10
15
20
25
30
35
r=0.184
Medium Control siRNA Fas siRNA
A
ct
iv
e 
Ca
sp
as
e-
3 
(%
)
0
5
10
15
20
25
- cytokine 
+ cytokine 
**
9-day Study
+ Jo2
+ Jo2
A B
DC
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558 B.R. Burkhardt et al. / FEBS Letters 580 (2006) 553–560not aﬀect Caspase-3 activity (Fig. 5C and D), an observation
that conﬁrmed the importance of cell surface Fas in mediating
cytokine-induced b cell apoptosis. NIT-1 cell apoptosis is char-
acterized by loss of adherence and Caspase-3 activity. To pro-
vide additional assessments of the siRNA eﬀects on cell
damage, ﬂoating cells following cytokines and Jo2 exposure
were harvested and counted. The 9-day treatment with Fas
siRNA markedly reduced the percentage of ﬂoating cells from
approximately 30% to 8% (data not shown), in accordance
with the Caspase-3 data.
We next tested the eﬃciency of Fas siRNA in suppressing
Fas expression and apoptosis in bTC-3 cells. Cytokine expo-
sure induced a more than 6-fold increase in Fas mRNA tran-
scripts, which was signiﬁcantly reduced by 48-h pretreatment
with Fas siRNA by 70% upon cytokine induction, as assessed
by semi-quantitative and real-time RT-PCR (Fig. 6A and B).
These studies were followed by ﬂow cytometric analysis of cell
surface Fas. Cytokine exposure increased the percentage of
surface Fas-expressing cells from 25.1% to 50.5%, which was
reduced to 28.1% by Fas siRNA, a percentage similar to that
of untreated cells (Fig. 6C). This result was further conﬁrmed
by immunostaining of Fas protein on bTC-3 cells (Fig. 7A–C
and G). Cytokine treatment not only increased the number of
Fas+ cells (from 31 ± 9.5% to 67 ± 12.1%), but also elevated
the Fas expression level. Pretreatment with Fas siRNA for 9
days markedly reduced the percentage of Fas+ cells to
39 ± 7.2% (P < 0.05) and resulted in diminished staining inten-
sity. Furthermore, suppression of Fas expression was accom-
panied by a signiﬁcant reduction in Fas-mediated cell deathFig. 6. Fas siRNA suppresses the cytokine-induced Fas mRNA and cell
ampliﬁcation of the Fas and GAPDH mRNA levels was performed using tot
Fas siRNA/cytokine treated cells (3). M, 100 bp molecular weight marker. A
(B) Real-time RT-PCR of Fas mRNA. Fas mRNA levels were normalized by
Flow cytometric proﬁles of cell surface Fas on bTC-3 cells subject to diﬀerent
siRNA/cytokine treated (red line). Percentage of cells with surface Fas is prfollowing incubation with Jo2 antibody and protein G, as eval-
uated by TUNEL assay (Fig. 7D–F and H). The percentage of
apoptotic cells following cytokine incubation was reduced by
Fas siRNA from 14.0 ± 3.2% to 6.8 ± 1.9% (P < 0.05), a value
close to that of untreated cells (4.0 ± 0.6%).
In summary, we have developed siRNA molecules that can
suppress Fas expression with high eﬃciency and protect trans-
formed b cells from Fas-mediated, cytokine-stimulated apop-
tosis. These data provide proof of concept and demonstrate
the potential of protecting b cells with Fas siRNA for islet
preservation. To extend this ﬁnding to improve islet trans-
plants, we need to ex vivo deliver Fas siRNA into primary is-
lets prior to transplantation. We and others [31] have
attempted liposomal transfection of intact mouse islets, but
approximately 10–20% of the islet cells were transfected by this
means (data not shown). Thus, we will use viral vectors to ex-
press small hairpin RNA (shRNA) targeting Fas in islet cells in
future studies. Several types of viruses have shown high trans-
duction eﬃciency in primary islets [32–34]. An alternative ap-
proach is to deliver siRNA molecules in vivo. Recent studies
have reported successful introduction of siRNA into pancre-
atic islet cells following intravenous administration or in situ
perfusion [31,35]. Moreover, double-stranded siRNAs are
resistant to biodegradation in human plasma [36], and have
demonstrated stable silencing eﬀects in mouse liver and kidney
for up to 10 days [16–18,37]. As immune-induced b cell death is
mediated by multiple mechanisms and eﬀectors, siRNA can be
designed to target various pro-inﬂammatory and pro-apopto-
tic molecules including Fas, iNOS, perforin, and cytokinesurface Fas increase in bTC-3 cells. (A) Semiquantitative RT-PCR
al RNA isolated from untreated cells (1), cytokine-treated cells (2) and
representative gel picture from two independent experiments is shown.
18s rRNA, and the values of untreated cells were set at 1. \P < 0.01. (C)
treatments: untreated (black line), cytokine-treated (blue line) and Fas
esented for each condition.
Fig. 7. Fas siRNA inhibits cytokine-induced Fas expression and Fas-mediated apoptosis in bTC-3 cells. Cells were divided in 3 groups: (1) untreated
(incubations 1 and 2) followed by 24-h Jo2 antibody and protein G (incubation 3); (2) untreated (incubation 1), 16-h cytokines (incubation 2), 24-h
Jo2 antibody and protein G (incubation 3); (3) 9-day Fas siRNA (incubation 1), 16-h cytokines (incubation 2), 24-h Jo2 antibody and protein G
(incubation 3). All cells were cultured for the same length of time in parallel. Immunostaining of Fas (A–C) and TUNEL assay of apoptosis (D–F)
were performed on cells untreated (A, D), cytokine treated (B, E) or Fas siRNA/cytokine treated (C, F). Fas was stained blue and nuclei were stained
red. Apoptotic cells (indicated by red arrows) appeared green under ﬂuorescent microscopy with nuclei labeled with DAPI (blue). Percentage of Fas+
cells (G) and TUNEL+ cells (H) were calculated from 12 randomly picked ﬁelds (10 · ) per group. \P < 0.05.
B.R. Burkhardt et al. / FEBS Letters 580 (2006) 553–560 559receptors to potentially protect b cells from immune destruc-
tion. Thus, siRNA-directed suppression of molecules involved
in islet cell death warrants further exploration for preventing
diabetes and improving islet transplantation.
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